Unlocking the Immune System to Attack Cancer    


Neon Therapeutics (NASDAQ: NTGN) is a clinical-stage immuno-oncology company leading in the field of neoantigen-targeted therapies and dedicated to transforming the treatment of each patient’s cancer by directing the immune system towards neoantigens. We have pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies using two distinct approaches. In NEON / ONE, these neoantigens are specific to each individual. In NEON / SELECT, these neoantigens are shared across subsets of patients and tumor types. Our most advanced product candidate is NEO‑PV‑01, a personal neoantigen vaccine, that is currently being evaluated in a Phase 1b open‑label clinical trial for patients with metastatic melanoma, non‑small cell lung cancer or bladder cancer.


Year Invested: 2015
Location: Cambridge, Mass.
Visit: neontherapeutics.com

Recent News

March 11, 2019
Neon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

March 4, 2019
Neon Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

February 27, 2019
Neon Therapeutics to Present at the American Association for Cancer Research Annual Meeting

Read More News

Associated Team Members

Robert Kamen, Ph.D.
Venture Partner

Cary Pfeffer, M.D.
Partner

Robert Tepper, M.D.
Partner

Stephen Sherwin, M.D.
Venture Partner

Ton Schumacher, Ph.D.
Venture Partner